<DOC>
	<DOC>NCT00688116</DOC>
	<brief_summary>An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)</brief_summary>
	<brief_title>Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors</brief_title>
	<detailed_description>This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.</detailed_description>
	<criteria>Patients must be documented to be refractory or not candidates for current approved therapies. Must have anECOG status 02. Peripheral neuropathy ?2. Must have acceptable organ and marrow function per protocol parameters. No clinically significant ventricular arrythmias or ischemia. Must not be pregnant or breastfeeding. No chemotherapy or radiation within 3 weeks.. No previous radiation to &gt;25% of total bone marrow. No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation. No primary brain tumors or active brain metastases. No use of any investigational agents within 4 weeks. No treatment with chronic immunosuppressants. No uncontrolled, intercurrent illness.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>metastatic cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>histologically or cytologically confirmed non-hematological malignancy that is metastatic or unresectable</keyword>
	<keyword>STA-9090</keyword>
	<keyword>ganetespib</keyword>
</DOC>